ResearcherUniversity of OtagoActive in the last 2 years
Amanda Landers
Matched on ORCID iD 0000-0002-7385-3739; OpenAlex author ID A5081155361. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper
Papers 8
- Navigating pain and appetite challenges in palliative care for pancreatic cancer: insights from a national, longitudinal consecutive cohort study. Co-author DOI 10.1007/s00520-025-09402-z↗
- Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study. Co-author DOI 10.1007/s00520-024-08604-1↗
- Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia. Co-author DOI 10.1016/j.pan.2024.10.008↗
- Recruitment of participants with pancreatic cancer to a mixed media study for optimal recruitment in an Australasian survey of pancreatic enzyme replacement. Co-author DOI 10.1136/bmjopen-2023-076242↗
- Enzyme replacement in advanced pancreatic cancer: patient perceptions. Co-author DOI 10.1136/bmjspcare-2019-002153↗
- The Impact of Pancreatic Enzyme Replacement Therapy on Patients With Advanced Pancreatic Adenocarcinoma: A Systematic Review and Narrative Synthesis. Co-author DOI 10.1097/mpa.0000000000002049↗
- The effectiveness of pancreatic enzyme replacement therapy for malabsorption in advanced pancreatic cancer, a pilot study. Co-author DOI 10.1177/1178224218825270↗
- Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. Co-author DOI 10.1136/bmjspcare-2014-000694↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Helen J. Brown · 7 shared papers, 2016–2024 · strength 1.33
- Paper Enzyme replacement in advanced pancreatic cancer: patient perceptions. DOI 10.1136/bmjspcare-2019-002153↗
- Paper Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australi… DOI 10.1007/s00520-024-08604-1↗
- Paper Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey ac… DOI 10.1016/j.pan.2024.10.008↗
- Meera Ruth Agar · 4 shared papers, 2023–2025 · strength 0.85
- Paper Navigating pain and appetite challenges in palliative care for pancreatic cancer: insights from a national, longitudina… DOI 10.1007/s00520-025-09402-z↗
- Paper Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australi… DOI 10.1007/s00520-024-08604-1↗
- Paper Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey ac… DOI 10.1016/j.pan.2024.10.008↗
- John Albert Windsor · 3 shared papers, 2023–2024 · strength 0.60
- Paper Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australi… DOI 10.1007/s00520-024-08604-1↗
- Paper Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey ac… DOI 10.1016/j.pan.2024.10.008↗
- Paper Recruitment of participants with pancreatic cancer to a mixed media study for optimal recruitment in an Australasian su… DOI 10.1136/bmjopen-2023-076242↗
- Mariana S. Sousa · 1 shared paper, 2025 · strength 0.25
- David Goldstein · 1 shared paper, 2025 · strength 0.25
- Nadia N. Khan · 1 shared paper, 2025 · strength 0.25
- David C. Currow · 1 shared paper, 2025 · strength 0.25
- Sayali A. Pendharkar · 1 shared paper, 2022 · strength 0.20
- Robert Matthew Strother · 1 shared paper, 2019 · strength 0.16
- Wendy Muircroft · 1 shared paper, 2016 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.